What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - ' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.' Open Protocol code: NN9388-7700 EudraCT code: No aplica Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Soler Romeo, Maria Jose Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH-1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF) Open Protocol code: GS-US-563-5925 EudraCT code: No aplica Research group: Infectious Diseases Service: Infectious Principal investigator: Curran Fàbregas, Adria Pathology: Certes malalties infeccioses i parasitàries Phase: Fase III Status: Recruiting volunteers “Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy Open Protocol code: NN9388-7864 EudraCT code: No aplica Research group: Diabetes and Metabolism Service: Endocrinology Principal investigator: Ortiz Zuñiga, Angel Michael Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2 Open Protocol code: D7261C00001 EudraCT code: No aplica Research group: Diabetes and Metabolism Service: Endocrinology Principal investigator: Ciudin Mihai, Andreea Pathology: Malalties endocrines, nutricionals i metabòliques Phase: Fase II Status: Recruiting volunteers A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84 Open Protocol code: SPL84-002 EudraCT code: No aplica Research group: Pneumology Service: Pneumology Principal investigator: Álvarez Fernandez, Antonio Pathology: Malalties del sistema respiratori Phase: Fase II Status: Recruiting volunteers Professionals Juan Fernando Fuentes Cabrera I'm a doctor specializing in Otorhinolaryngology and Head and Neck Surgery. Within the ENT department , I work in the head and neck section, with special interest in head and neck cancer and minimally invasive techniques such as robotic surgery, as well as benign pathology in this area. I have a Professionals Alba Maria Jiménez Masip Professionals Juan Ignacio Rodriguez Gómez Professionals Rucsanda Pinteac Professionals Anika Pupak I am a Local Research Coordinator at Barcelona site (Vall d’Hebron) of the European Spine Study Group, which I joined in 2023. Professionals Emilie Anderssen Nordahl Year 2025 Títol Complet Contractació del servei d'assegurances de salut privada, a través del pla de compensació flexible, destinat a tot el personal de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient ASSEGURANCES DE SALUT (PCF) Codi 24979060 Data publicació Thu, 02/06/2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESERT Year 2025 Títol Complet Institutional framework agreement for technical and support services in developement of competitive proposals (excluding ERC proposals) (Lot 1) and development of competitive proposals (ERC proposals) (Lot 2) and support services in the post-award management of competitive projects (Lot 3) of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient FRAMEWORK AGREEMENT FOR TECHNICAL AND SUPPORT SERV Codi 24979135 Data publicació Fri, 02/07/2025 - 12:00 Documentos (enllaços) TENDER NOTICE SPECIFIC ADMINISTRATIVE BIDDING CONDITIONS APPENDIX 1.1 PCAP APPENDIX 1.2 PCAP APPENDIX 1.3 PCAP DOCUMENT OF TECHNICAL SPECIFICATIONS MAIN POINTS ON THE DIGITAL TOOL DEUC DEUC XML. INSTRUCTIONS FOR FILLING DEUC AGREEMENT ON THE NEED SUFFICIENCY OF CREDIT CERTIFICATE RESOLUTION ON THE APPOINTMENT OF THE CONTRACT AWARDING COMMITTEE RESOLUTION FOR THE APPROVAL OF THE TENDER RESOLUTION TO MDODIFY ENVELOPE NUM. 3 Professionals Ana Lucea Peña Professionals Fátima Sol Cabrera A Phase 2a, Open-label, Multicenter, Platform Trial to Assessthe Safety, Tolerability, and Efficacy of Inebilizumab andBlinatumomab in Subjects With Select Autoimmune Diseases Open Protocol code: 20240033 EudraCT code: No aplica Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Bestard Matamoros, Oriol Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Estudio clínico de fase 3, aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de molnupiravir (MK-4482) en adultos no hospitalizados con COVID-19 y alto riesgo de progresión de la enfermedad Open Protocol code: MK-4482-023 EudraCT code: No aplica Research group: Infectious Diseases Service: Infectious Principal investigator: Len Abad, Oscar Pathology: Certes malalties infeccioses i parasitàries Phase: Fase III Estudio de fase 1 del inhibidor de menina ziftomenib en combinación con quimioterapia en niños con leucemia aguda recidivante o resistente al tratamiento con reordenamientos de los genes KMT2A o NUP98, o con mutación en el gen NPM1 Open Protocol code: ITCC-101/APAL2020K EudraCT code: No aplica Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Principal investigator: Murillo Sanjuán , Laura Pathology: Tumors Phase: Fase I A Randomized, Double-masked, Multicenter, 3-Arm Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema Open Protocol code: EYE-RES-102 EudraCT code: No aplica Research group: Ophtalmology Service: Ophthalmology Principal investigator: Garrido Marin, Marta Pathology: Malalties de l’ull i dels seus annexos Phase: Fase III A phase 2a, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and pharmacodynamic effects of biib122 in participants with lrrk2-associated parkinson’s disease (lrrk2-pd) Open Protocol code: DNLI-C-0009 EudraCT code: _ Research group: Neurodegenerative Diseases Service: Neurology Principal investigator: Hernández Vara, Jorge Pathology: Malalties del sistema nerviós Phase: Fase II Pagination First page « Previous page ‹ … Page 1395 Page 1396 Current page 1397 Page 1398 Page 1399 … Next page › Last page »
Year 2025 Títol Complet Contractació del servei d'assegurances de salut privada, a través del pla de compensació flexible, destinat a tot el personal de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient ASSEGURANCES DE SALUT (PCF) Codi 24979060 Data publicació Thu, 02/06/2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESERT
Year 2025 Títol Complet Institutional framework agreement for technical and support services in developement of competitive proposals (excluding ERC proposals) (Lot 1) and development of competitive proposals (ERC proposals) (Lot 2) and support services in the post-award management of competitive projects (Lot 3) of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient FRAMEWORK AGREEMENT FOR TECHNICAL AND SUPPORT SERV Codi 24979135 Data publicació Fri, 02/07/2025 - 12:00 Documentos (enllaços) TENDER NOTICE SPECIFIC ADMINISTRATIVE BIDDING CONDITIONS APPENDIX 1.1 PCAP APPENDIX 1.2 PCAP APPENDIX 1.3 PCAP DOCUMENT OF TECHNICAL SPECIFICATIONS MAIN POINTS ON THE DIGITAL TOOL DEUC DEUC XML. INSTRUCTIONS FOR FILLING DEUC AGREEMENT ON THE NEED SUFFICIENCY OF CREDIT CERTIFICATE RESOLUTION ON THE APPOINTMENT OF THE CONTRACT AWARDING COMMITTEE RESOLUTION FOR THE APPROVAL OF THE TENDER RESOLUTION TO MDODIFY ENVELOPE NUM. 3
